Current and future prospects for hemophilia gene therapy

Area of Science:

• * Hematology
• * Gene Therapy
• * Viral Vector Technology

Background:

• * Hemophilia is a group of inherited bleeding disorders.
• * Current treatments involve factor replacement therapy, which can be burdensome.
• * Gene therapy offers a potential alternative for long-term treatment of bleeding disorders.

Purpose of the Study:

• * To review recent literature on hemophilia gene transfer and therapy.
• * To discuss current and pending clinical efforts utilizing gene therapy.
• * To analyze trends in the field, focusing on recombinant Adeno-associated viral (rAAV) vectors.

Main Methods:

• * Review of preclinical and translational research over the past 20 years.
• * Focus on studies employing recombinant Adeno-associated viral (rAAV) vector-mediated gene transfer.
• * Analysis of data from active clinical trials using rAAV vectors.

Main Results:

• * Significant advancements in achieving therapeutic factor levels through modified rAAV vectors.
• * Emerging patterns in treatment outcomes based on different rAAV vector types.
• * Identification of potential immune/inflammatory and oncogenic risks associated with gene therapy.

Conclusions:

• * Recombinant Adeno-associated viral (rAAV) vector-mediated gene transfer is the leading approach in hemophilia gene therapy.
• * While promising results have been achieved, ongoing research is crucial for vector optimization and safety.
• * Careful consideration of potential risks is necessary for the successful clinical translation of hemophilia gene therapy.